These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 25069814)
21. Thrombin generation test as a marker for high risk venous thrombosis pregnancies. Joly BS; Sudrié-Arnaud B; Barbay V; Borg JY; Le Cam Duchez V J Thromb Thrombolysis; 2018 Jan; 45(1):114-121. PubMed ID: 29032523 [TBL] [Abstract][Full Text] [Related]
22. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Eichinger S; Weltermann A; Philipp K; Hafner E; Kaider A; Kittl EM; Brenner B; Mannhalter C; Lechner K; Kyrle PA Thromb Haemost; 1999 Oct; 82(4):1232-6. PubMed ID: 10544904 [TBL] [Abstract][Full Text] [Related]
23. Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis. Eikelboom JW; Ivey L; Ivey J; Baker RI Blood Coagul Fibrinolysis; 1999 Jan; 10(1):1-5. PubMed ID: 10070829 [TBL] [Abstract][Full Text] [Related]
24. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. Speidl WS; Zeiner A; Nikfardjam M; Geppert A; Jordanova N; Niessner A; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K J Am Coll Cardiol; 2005 Jan; 45(1):30-4. PubMed ID: 15629369 [TBL] [Abstract][Full Text] [Related]
26. The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. Schambeck CM; Eberl E; Geisen U; Grossmann R; Keller F Thromb Haemost; 2001 May; 85(5):782-6. PubMed ID: 11372668 [TBL] [Abstract][Full Text] [Related]
27. Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis. Lisman T Semin Thromb Hemost; 2017 Mar; 43(2):178-184. PubMed ID: 27472427 [TBL] [Abstract][Full Text] [Related]
28. Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. Syrigos K; Grapsa D; Sangare R; Evmorfiadis I; Larsen AK; Van Dreden P; Boura P; Charpidou A; Kotteas E; Sergentanis TN; Elalamy I; Falanga A; Gerotziafas GT Oncologist; 2018 Nov; 23(11):1372-1381. PubMed ID: 30104289 [TBL] [Abstract][Full Text] [Related]
29. Factor IX-Padua enhances the fibrinolytic resistance of plasma clots. Ammollo CT; Semeraro F; Colucci M; Simioni P Thromb Haemost; 2014 Feb; 111(2):226-32. PubMed ID: 24136406 [TBL] [Abstract][Full Text] [Related]
30. Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation. Ding Q; Yang L; Zhao X; Wu W; Wang X; Rezaie AR Thromb Haemost; 2017 Feb; 117(3):479-490. PubMed ID: 27975099 [TBL] [Abstract][Full Text] [Related]
31. Hyperprothrombinaemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis. Binetti BM; Rotunno C; Tripodi A; Asti D; Semeraro F; Semeraro N; Colucci M Thromb Haemost; 2006 Apr; 95(4):606-11. PubMed ID: 16601829 [TBL] [Abstract][Full Text] [Related]
32. The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood. Kalweit G; Bach J; Huwer H; Winning J; Hellstern P Thromb Res; 2005; 116(1):33-9. PubMed ID: 15850606 [TBL] [Abstract][Full Text] [Related]
34. Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. Bolliger D; Szlam F; Levy JH; Molinaro RJ; Tanaka KA Br J Anaesth; 2010 Mar; 104(3):318-25. PubMed ID: 20133450 [TBL] [Abstract][Full Text] [Related]
35. [Diagnosis of thrombosis by hemostatic markers]. Wada H; Matsumoto T; Yamashita Y Nihon Rinsho; 2014 Jul; 72(7):1232-6. PubMed ID: 25163313 [TBL] [Abstract][Full Text] [Related]
36. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Folkeringa N; Coppens M; Veeger NJ; Bom VJ; Middeldorp S; Hamulyak K; Prins MH; Büller HR; van der Meer J Thromb Haemost; 2008 Jul; 100(1):38-44. PubMed ID: 18612536 [TBL] [Abstract][Full Text] [Related]
37. The influence of corticosteroids on hemostasis in healthy subjects. Majoor CJ; Sneeboer MM; de Kievit A; Meijers JC; van der Poll T; Lutter R; Bel EH; Kamphuisen PW J Thromb Haemost; 2016 Apr; 14(4):716-23. PubMed ID: 26791678 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability. Stegnar M; Cuderman TV; Bozic M Clin Chem Lab Med; 2007; 45(1):40-6. PubMed ID: 17243913 [TBL] [Abstract][Full Text] [Related]
40. Factor V Leiden in Greek thrombophilic patients: relationship with activated protein C resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1 + 2. Lambropoulos AF; Foka Z; Makris M; Daly M; Kotsis A; Makris PE Blood Coagul Fibrinolysis; 1997 Nov; 8(8):485-9. PubMed ID: 9491265 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]